The U.S. Food and Drug Administration has approved Ilaris® (canakinumab) for the treatment of children as young as two years of age with active systemic juvenile idiopathic arthritis (SJIA).
SJIA is a rare but severe form of childhood arthritis. The condition causes fever, rash, and joint pain, and can affect children as young as two. SJIA can be life-threatening, and treatment options have been limited.
Ilaris inhibits a protein known as IL-1 beta. Overproduction of this protein plays an important role in some types of inflammatory diseases. For the treatment of SJIA, Ilaris is given once a month as a subcutaneous (under-the-skin) injection.
The approval of Ilaris for SJIA was based on the results of two Phase III clinical trials. Both trials enrolled children and adolescents between the ages of 2 and 19 years. In the first study, 84% of patients treated with Ilaris had at least a 30% improvement of symptoms; only 10% of patients in the placebo group had this level of improvement. In the second study, Ilaris allowed many patients to reduce or eliminate corticosteroid use, and also resulted in a lower risk of arthritis flares than placebo. Side effects of Ilaris included an increased risk of serious infections.
Update To Treat To Target Recommendations for Ankylosing Spondylitis
Experts update treatment recommendations for ankylosing spondylitis.
Ilaris provides a new treatment option for patients with active SJIA.
Source: Novartis press release. Novartis drug Ilaris® approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis. May 10, 2013.